A further study revealed that ipilimumab-treated melanoma patients with New York esophageal squamous cell carcinoma-1 (NY-ESO-1)-specific serum antibodies and CD8+ T cells recognizing NY-ESO-1-derived peptides experienced more frequent clinical benefit than those with undetectable CD8+ T cell response [36]. The gene discussed is CD8A; the disease is melanoma.